BP/ DR Assay
Product Overview
EasyNAT® BP/ DR Assay is an automated, in vitro nucleic acid amplification test used for qualitative diagnosis of deoxyribonucleic acid (DNA) of Bordetella pertussis (BP) and the mutation site accounted for the macrolides resistance, i.e., A2047G in the 23S rRNA, in human nasopharyngeal swab specimens.
- Result botained within 54 mins
- Direct diagnosis design to provide an accurate LOD: 500 copies/mL
- Directly detects nucleic acid and the drug resistance gene of B. pertussis in samples
Ongoing Challanges
B. pertussis infection.B.pertussis is the causative agent of pertussis, which is highly contagious and occurs in infants and young children, and is clinically characterized by gradually worsening cough, a typical paroxysmal, spasmodic cough, and a deep chicken cry like inspiratory roar at the end of the cough, with a duration of up to 2 to 3 months. transmissibility, ability to cause a wide range of diseases, and impact on vulnerable populations.
A new generation of macrolide antibiotics has long been the drugs of choice for the treatment of pertussis. The A2047G mutation in the 23S rRNA gene of B. pertussis is highly associated with drug resistance in B. pertussis. At present, The culture method is difficult and has a long cycle; the serological method is fast, but the sensitivity and specificity are poor and drug resistance cannot be detected.
Clinical Value
- Dramatically improve the experience of patience.
- Providing correct guidance for exchanging antibiotic and preventions.
- Lowers the lab’s burden for antenatal screening.
Product Resources
EasyNAT® BP/ DR Assay
Brochure
